Cargando…

2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report

Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Wei, Zhao, Nan, Zhang, Manze, Li, Zhihua, Wang, Ning, Shen, Wennan, Dong, Yuemei, Nie, Yanli, Li, Zhaoxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598860/ https://www.ncbi.nlm.nih.gov/pubmed/37886174 http://dx.doi.org/10.3389/fonc.2023.1242460

Ejemplares similares

Extraskeletal Ewing’s sarcoma of the mediastinum: Case report
por: Caltavituro, Aldo, et al.
Publicado: (2023)

Locally Advanced Non Small Cell Lung Cancer: The Case for Radiation Dose De-escalation in the Management of the Mediastinum
por: Soyfer, Viacheslav, et al.
Publicado: (2019)

Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era
por: Civantos, Francisco J., et al.
Publicado: (2020)

Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer
por: Nie, Duorui, et al.
Publicado: (2021)

“Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
por: Kolling, Stefan, et al.
Publicado: (2020)

Computed Tomography-Based Radiomics for Differentiation of Thymic Epithelial Tumors and Lymphomas in Anterior Mediastinum
por: He, Wenzhang, et al.
Publicado: (2022)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
por: Hu, Chen, et al.
Publicado: (2021)

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
por: Mei, Lihong, et al.
Publicado: (2023)

Cervical squamous cell carcinoma of unknown primary: Oncological outcomes and prognostic factors
por: Meulemans, Jeroen, et al.
Publicado: (2022)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
por: Boutros, Andrea, et al.
Publicado: (2021)

An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma
por: Huang, Yaxuan, et al.
Publicado: (2022)

Perspectives on Immunotherapy of Metastatic Colorectal Cancer
por: Dai, Yongjiu, et al.
Publicado: (2021)

Significance of the Neutrophil-to-Lymphocyte Ratio in p16-Negative Squamous Cell Carcinoma of Unknown Primary in Head and Neck
por: Xu, Chunmiao, et al.
Publicado: (2020)

Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA
por: Xue, Yuwen, et al.
Publicado: (2023)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Mechanisms of Cancer Resistance to Immunotherapy
por: Bai, Rilan, et al.
Publicado: (2020)

Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin
por: Bonatelli, Murilo, et al.
Publicado: (2021)

Deep Learning-Based Protein Features Predict Overall Survival and Chemotherapy Benefit in Gastric Cancer
por: Zhao, Xuefei, et al.
Publicado: (2022)

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
por: Welters, Marij J. P., et al.
Publicado: (2020)

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
por: Alberti, Andrea, et al.
Publicado: (2022)

Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy
por: Zhu, Liqiong, et al.
Publicado: (2022)

Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients
por: Zhu, Yankun, et al.
Publicado: (2023)

Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
por: Bochtler, Tilmann, et al.
Publicado: (2019)

Particle Therapy for Breast Cancer: Benefits and Challenges
por: Luo, Wanrong, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study
por: Chen, Zhiju, et al.
Publicado: (2020)

Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases
por: Huang, Mingzhu, et al.
Publicado: (2022)

An 11-Gene Signature Based on Treatment Responsiveness Predicts Radiation Therapy Survival Benefit Among Breast Cancer Patients
por: Shen, Junjie, et al.
Publicado: (2022)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy
por: He, Zi-Xuan, et al.
Publicado: (2022)

The Survival Benefit and Safety of Splenectomy for Gastric Cancer With Total Gastrectomy: Updated Results(†)
por: Yang, Kun, et al.
Publicado: (2021)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Qian, Jie, et al.
Publicado: (2021)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
por: Shi, Xiaoxi, et al.
Publicado: (2021)

90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary
por: Zhang, Yi, et al.
Publicado: (2021)

Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary
por: Yu, Bo, et al.
Publicado: (2022)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4d7uqh3snof1lvl6jla9i9ff4m